Clinical trials: Malignant Gliomas
Brain Metastasis, Spinal Tumors
Study of SBRT Efficacy on Intra and Extra -Cranial Tumors or Metastasis in Pediatrics Population (SBRT Pediatrics)
The purpose of this study is to evaluate the efficacy of hypofractionated stereotactic radiation treatments (SBRT) on children, teenagers and young adults malignant tumors.
- Conditions
- Brain Metastasis, Spinal Tumors, Lung Tumors, Ependymoma
- Trial name
- SBRT (NCT02013297)
- Testing
- SBRT treatment
- Where
- 15 sites in France
- Volunteers
- 61 people
- Sponsor
- Centre Leon Berard
Glioma
Multiparametric Metabolic and Hypoxic PET/MRI Imaging Substudy in Gliomas
This substudy will investigate a new imaging approach using positron emission tomography (PET) and two investigational drugs ([18F]FET and [18F]FMISO) to see if the imaging results will help with the placement of catheters for…
- Trial name
- NCT07778979
- Testing
- [18F]FMISO-PET with contrast-enhanced MRI
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Alabama at Birmingham
Glioblastoma, Brain Metastases
PET/CT Imaging of Malignant Brain Tumors With 124I-NM404
The purpose of this study is to evaluate diagnostic imaging techniques using 124I-NM404 PET/CT in humans with brain metastases and GBMs.
- Trial name
- NCT01516905
- Testing
- NM404
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Wisconsin, Madison
Supratentorial Neoplasms, Malignant, Malignant Glioma
HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors
This study is a clinical trial to determine the safety of injecting G207 (a new experimental virus therapy) into a recurrent or progressive brain tumor.
- Conditions
- Supratentorial Neoplasms, Malignant, Malignant Glioma, Glioblastoma, Anaplastic Astrocytoma
- Trial name
- NCT02457845
- Testing
- G207
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Gregory K. Friedman, MD
Low Grade Glioma (LGG) of Brain With BRAF Aberration, High Grade Glioma (HGG) of the Brain With BRAF Aberration
A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration
This phase I/II trial is designed to study the side effects, best dose and efficacy of adding hydroxychloroquine to dabrafenib and/or trametinib in children with low grade or high grade brain tumors previously treated with…
- Conditions
- Low Grade Glioma (LGG) of Brain With BRAF Aberration, High Grade Glioma (HGG) of the Brain With BRAF Aberration, Low Grade Glioma of Brain With Neurofibromatosis Type 1
- Trial name
- NCT04201457
- Testing
- Dabrafenib, Trametinib, Hydroxychloroquine
- Where
- 15 sites in United States
- Volunteers
- 57 people
- Sponsor
- Pediatric Brain Tumor Consortium
Glioma, Glioblastoma
Infigratinib in Recurrent High-Grade Glioma Patients
This trial is an open-label, multicenter, Phase 0 trial that will enroll up to 20 participants with recurrent high-grade glioma with FGFR1 K656E or FGFR3 K650E mutation or FGFR3-TACC3 translocation which are scheduled for…
- Conditions
- Glioma, Glioblastoma, GBM
- Trial name
- NCT04424966
- Testing
- Infigratinib
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Nader Sanai
Childhood Soft Tissue Sarcoma, Childhood Liver Cancer
Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of liposomal doxorubicin in treating children who have…
- Conditions
- Childhood Soft Tissue Sarcoma, Childhood Liver Cancer, Bone Cancer, Brain Tumor
- Trial name
- NCT00019630
- Testing
- doxorubicin HCl liposome
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Capecitabine and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Nonmetastatic Brain Stem Glioma or High-Grade Glioma
RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00357253
- Testing
- capecitabine, radiation therapy
- Where
- 12 sites in United States
- Volunteers
- 24 people
- Sponsor
- Pediatric Brain Tumor Consortium
Glioma
Evaluation of Clinical Efficacy and Safety of Specific Mode Electroacupuncture Stimulation for Paclitaxel Across BBB Delivery in Patients With Postoperative Recurrence of Malignant Glioma: A Single-arm Trial
Gliomas are the most common type of primary brain tumors, with the main treatment modalities including surgery, radiotherapy, and chemotherapy.
- Trial name
- NCT06818331
- Testing
- SMES+PTX, Paclitaxel, Specific mode electroacupuncture stimulation
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The Third Affiliated hospital of Zhejiang Chinese Medical University
Malignant Glioma, Anxiety
Psychological Intervention For Brain Tumor Caregivers
This study is testing a supportive psychosocial intervention for caregivers of people who have malignant brain tumors such as gliomas or other high-grade primary brain tumors.
- Conditions
- Malignant Glioma, Anxiety, Caregiver Burden, Malignant Brain Tumor
- Trial name
- NCT04109209
- Testing
- Psychosocial Intervention Group, Usual Care Group
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Glioma, Glioblastoma
Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption
The purpose of this study is to evaluate the safety of the ExAblate Model 4000 Type 2 used as a tool to disrupt the BBB (blood brain barrier) in patients with high grade glioma undergoing standard of care therapy.
- Trial name
- NCT03551249
- Testing
- Focused ultrasound (FUS)
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- InSightec
Recurrent Glioblastoma
Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas
The purpose of this study is to evaluate both enzastaurin and bevacizumab in the treatment of recurrent malignant gliomas.
- Trial name
- NCT00586508
- Testing
- enzastaurin, bevacizumab, Enzyme-inducing antiepileptic drugs (EIAED)
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Eli Lilly and Company
Malignant Brain Stem Tumor, Glioma
Anlotinib to Malignant Brainstem Glioma
This study is a single-arm, open-label, phase II study of anlotinib combined with radiation in the treatment of patients with malignant brainstem glioma.
- Trial name
- NCT04668508
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Zhejiang Cancer Hospital
Glioblastoma Multiforme, Glioma of Brain
A Phase 0/I Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection
In the proposed trial, patients will be administered ribociclib+everolimus prior to surgical resection of their tumor. Recurrent GBM patients will be randomized into one of the three time-interval cohorts for the first two dose…
- Trial name
- NCT03834740
- Testing
- Ribociclib, Everolimus
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
Low Grade Glioma (LGG), High Grade Glioma (HGG)
Confocal Laser Endomicroscopy for Brain Tumors
Confocal Laser Endomicroscopy (CLE) could be a useful tool for real-time diagnosis of brain lesions (initial diagnosis or follow-up post resection to check for residual dysplasia) and real-time assessment of resections margins…
- Trial name
- GLIOFOCAL (NCT02240758)
- Testing
- confocal endomicroscopy with the CELLVIZIO® system (Mauna Kea technology)
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Hospices Civils de Lyon
High Grade Gliomas, Hypoxia Brain
Brain Radiotherapy Imaging for High-grade Glioma Using Hypoxia Targeting Through Oxygen-Enhanced Response
High-grade gliomas (HGGs) are the most common type of brain cancer in adults. Life expectancy for patients with HGGs is low. Radiotherapy aims to cure the tumour, but this is hard because HGGs are resistant to treatment.
- Conditions
- High Grade Gliomas, Hypoxia Brain, Glioblastoma (GBM), Brain Neoplasms, Adult
- Trial name
- BRIGHTER (NCT07670455)
- Testing
- Oxygen-Enhanced MRI (OE-MRI)
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- The Leeds Teaching Hospitals NHS Trust
High Grade Glioma
Phase 1 Study of Locoregional Injections of Ex Vivo Expanded Natural Killer Cells
Each patient will receive up to 12 cycles of TGFβi NK cell infusions. Each cycle will be of 4 weeks duration. During the first 3 weeks, TGFβi NK cells will be infused once weekly. The 4th week will be a rest week.
- Trial name
- NCT04254419
- Testing
- NK cells
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Nationwide Children's Hospital
Glioblastoma
Phase I Trial of pH Resections of GBM at VA
Glioblastoma is an infiltrating tumor that is difficult to visualize in surgery and on standard images. A special pH (acid-base) related magnetic resonance imaging (MRI) has been developed to better see infiltrating tumor.
- Trial name
- NCT07218367
- Testing
- pH MRI based resection of GBM
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- VA Office of Research and Development
Brain Gliomas, High-Grade Gliomas
Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection
B7-H3 is expressed at low levels in normal tissues but overexpressed in various tumor tissues. The ubiquitous expression of B7-H3 in tumors of different grades is a key feature for brain gliomas.
- Conditions
- Brain Gliomas, High-Grade Gliomas, GBM
- Trial name
- NCT06018363
- Testing
- Allogenic B7-H3 CAR-γδT cell(QH104)
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Dushu Lake Hospital Affiliated to Soochow University
Recurrent High-grade Glioma
Ultra-low Dose Bevacizumab Plus Temozolomide for Recurrent High-grade Gliomas
This study is to evaluate the effectiveness of ultra-low dose Bevacizumab plus Temozolomide for recurrent high-grade gliomas.
- Trial name
- NCT02416999
- Testing
- Ultra-low dose Bevacizumab, Temozolomide
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Hebei Yanda Hospital